Author:
Mistry Dylan A.,Wang Jenny Y.,Moeser Mika-Erik,Starkey Thomas,Lee Lennard Y. W.
Abstract
Abstract
Background
Lateral flow devices (LFDs) are viral antigen tests for the detection of SARS-CoV-2 that produce a rapid result, are inexpensive and easy to operate. They have been advocated for use by the World Health Organisation to help control outbreaks and break the chain of transmission of COVID-19 infections. There are now several studies assessing their accuracy but as yet no systematic review. Our aims were to assess the sensitivity and specificity of LFDs in a systematic review and summarise the sensitivity and specificity of these tests.
Methods
A targeted search of Pubmed and Medxriv, using PRISMA principles, was conducted identifying clinical studies assessing the sensitivity and specificity of LFDs as their primary outcome compared to reverse transcriptase polymerase chain reaction (RT-PCR) for the detection of SARS-CoV-2. Based on extracted data sensitivity and specificity was calculated for each study. Data was pooled based on manufacturer of LFD and split based on operator (self-swab or by trained professional) and sensitivity and specificity data were calculated.
Results
Twenty-four papers were identified involving over 26,000 test results. Sensitivity from individual studies ranged from 37.7% (95% CI 30.6–45.5) to 99.2% (95% CI 95.5–99.9) and specificity from 92.4% (95% CI 87.5–95.5) to 100.0% (95% CI 99.7–100.0). Operation of the test by a trained professional or by the test subject with self-swabbing produced comparable results.
Conclusions
This systematic review identified that the performance of lateral flow devices is heterogeneous and dependent on the manufacturer. Some perform with high specificity but a great range of sensitivities were shown (38.32–99.19%). Test performance does not appear dependent on the operator. Potentially, LFDs could support the scaling up of mass testing to aid track and trace methodology and break the chain of transmission of COVID-19 with the additional benefit of providing individuals with the results in a much shorter time frame.
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Patel R, Babady E, Theel ES, Storch GA, Pinsky BA, St George K, et al. PMC7157705; Report from the American society for microbiology COVID-19 international summit, 23 March 2020: value of diagnostic testing for SARS-CoV-2/COVID-19. mBio 2020;11(2).
2. O’Farrell B. Evolution in lateral flow–based immunoassay systems. Lateral flow immunoassay: Springer; 2009. p. 1-33.
3. Guglielmi G. Fast coronavirus tests: what they can and can’t do. Nature. 2020;585(7826):496–8.
4. Porte L, Legarraga P, Vollrath V, Aguilera X, Munita JM, Araos R, et al. Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples. Int J Infect Dis. 2020;99:328–33.
5. World Health Organisation. Laboratory testing strategy recommendations for COVID-19. 2020. https://apps.who.int/iris/handle/10665/331509. Accessed 12 Feb 2021.
Cited by
77 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献